CervoMed Inc. Common Stock
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company’s current work centers on advancing CNS-focused therapeutics designed to address degenerative diseases of the brain, with a lead program built around neflamapimod, an investigational orally administered small molecule intended to act on synaptic dysfunction and related neurodegenerative processes. CervoMed’s pipeline targets conditions such as dementia with Lewy bodies and other disorders affecting cognition and neurological function, reflecting its role in the specialized biopharmaceutical sector. As a public company, CervoMed operates within the broader healthcare innovation market, where clinical development, regulatory progress, and therapeutic differentiation are central to its business model. Headquartered in Boston, Massachusetts, CervoMed Inc. serves as a focused small-cap biotechnology participant developing novel approaches for unmet neurological needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John J. Alam M.D.
- Employees
- 15
- Headquarters
- Boston, MA, United States
- Website
- www.cervomed.com